Influenza continues to represent a major threat to public health, and the development of monoclonal antibodies (mAbs) that provide broad protection remains a key avenue for therapeutic development. Here, the authors demonstrate the molecular basis of neutralization for a human bnAb (PN-SIA28) against both endemic influenza A and emerging pathogens such as bat H17 and H18 viruses.
- Yulu Chen
- Fei Wang
- George F. Gao
